Patrick Y Wen

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    J Neurooncol 80:313-32. 2006
  2. pmc Current clinical development of PI3K pathway inhibitors in glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Neuro Oncol 14:819-29. 2012
  3. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Harvard Medical School, Center for Neuro Oncolgy, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:299-307. 2002
  4. ncbi request reprint Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
    Patrick Y Wen
    Harvard Medical School, Dana Farber Brigham and Women s Cancer Center, SW430D, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 6:733-54. 2006
  5. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
  6. doi request reprint Treatment of recurrent high-grade gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 22:657-64. 2009
  7. ncbi request reprint Novel therapies for meningiomas
    Patrick Y Wen
    Center for Neuro Oncology Dana Farber Brigham and Women s Cancer Center, and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Expert Rev Neurother 6:1447-64. 2006
  8. ncbi request reprint Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:1963-72. 2010
  9. doi request reprint Response assessment challenges in clinical trials of gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 12:68-75. 2010
  10. doi request reprint Medical therapies for meningiomas
    Patrick Y Wen
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    J Neurooncol 99:365-78. 2010

Research Grants

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    J Neurooncol 80:313-32. 2006
    ..Medications such as modafinil and methylphenidate have assumed an increasing role in the treatment of fatigue, while donepezil and memantine may be helpful with memory loss...
  2. pmc Current clinical development of PI3K pathway inhibitors in glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Neuro Oncol 14:819-29. 2012
    ....
  3. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Harvard Medical School, Center for Neuro Oncolgy, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:299-307. 2002
    ....
  4. ncbi request reprint Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
    Patrick Y Wen
    Harvard Medical School, Dana Farber Brigham and Women s Cancer Center, SW430D, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 6:733-54. 2006
    ..In this article, the current status of targeted molecular agents for malignant gliomas will be reviewed and strategies to improve their effectiveness will be discussed...
  5. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  6. doi request reprint Treatment of recurrent high-grade gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 22:657-64. 2009
    ..Although therapies for patients with recurrent high-grade gliomas are limited, there has been important progress recently. This review summarizes current treatments for recurrent high-grade gliomas with an emphasis on more novel approaches...
  7. ncbi request reprint Novel therapies for meningiomas
    Patrick Y Wen
    Center for Neuro Oncology Dana Farber Brigham and Women s Cancer Center, and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Expert Rev Neurother 6:1447-64. 2006
    ..In this review, the role of newly emerging novel therapies for meningiomas, with a focus on targeted molecular agents, will be discussed...
  8. ncbi request reprint Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:1963-72. 2010
    ..In this proposal, we present the recommendations for updated response criteria for high-grade gliomas...
  9. doi request reprint Response assessment challenges in clinical trials of gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 12:68-75. 2010
    ..This review discusses challenges that have emerged in assessing response in patients with gliomas and approaches being introduced to address them...
  10. doi request reprint Medical therapies for meningiomas
    Patrick Y Wen
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    J Neurooncol 99:365-78. 2010
    ....
  11. pmc Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    Neuro Oncol 11:853-60. 2009
    ..Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia...
  12. doi request reprint Malignant gliomas in adults
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Dana Farber corrected Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 359:492-507. 2008
  13. ncbi request reprint Malignant gliomas
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Cancer Institute, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 4:218-27. 2004
    ..Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies...
  14. ncbi request reprint Neurologic complications of solid tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St Boston, MA 02115, USA
    Neurol Clin 21:107-40, viii. 2003
    ..As systemic therapy improves for many of these tumors, patients are surviving longer and the incidence of neurologic complications is increasing...
  15. pmc Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neuro Oncol 9:354-63. 2007
    ..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted...
  16. ncbi request reprint Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:85-90. 2010
    ..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)...
  17. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
    ..nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. ..
  18. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
    ..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT...
  19. pmc Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  20. pmc Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Ave, Boston, MA 02215, USA
    Neuro Oncol 15:930-5. 2013
    ..Resistance to temozolomide is partially mediated by O(6)-methylguanine-DNA methyltransferase (MGMT). Because MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance...
  21. ncbi request reprint A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
    David A Reardon
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 19:900-8. 2013
    ..We hypothesized that patients with recurrent glioblastoma would exhibit differential antitumor benefit based on tumor PTEN/EGFRvIII status when treated with the antiangiogenic agent pazopanib and the ErbB inhibitor lapatinib...
  22. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
    ..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs...
  23. doi request reprint Phase II study of protracted daily temozolomide for low-grade gliomas in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
    Clin Cancer Res 15:330-7. 2009
    ..Protracted treatment with temozolomide potentially overcomes MGMT resistance and improves outcome. We conducted a phase II study of protracted daily temozolomide in adults with low-grade gliomas...
  24. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  25. pmc Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney St SW430B, Boston, MA 02115, USA
    J Neurooncol 96:211-7. 2010
    ..The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted...
  26. ncbi request reprint Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival
    Christina Chen
    Harvard Medical School, 250 Longwood Avenue, Boston, MA, 02115, USA
    J Neurooncol 115:267-76. 2013
    ..14, p = 0.004). Area of enhancing tumor at baseline can stratify survival in patients with recurrent HGG treated with bevacizumab. The extent of edema relative to enhancing area may have a prognostic role specific to Grade III HGG...
  27. pmc Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
    Eudocia C Quant
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:550-5. 2009
    ..Those patients with malignant gliomas who progressed despite a bevacizumab-containing regimen rarely responded to the second bevacizumab-containing chemotherapeutic regimen. In such patients, alternate therapies should be considered...
  28. pmc A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    A Gregory Sorensen
    A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:5296-300. 2009
    ..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials...
  29. ncbi request reprint Medical management of brain tumor patients
    Jan Drappatz
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Neurol Clin 25:1035-71, ix. 2007
    ..Effective medical management results in decreased morbidity and mortality and improved quality of life for affected patients...
  30. ncbi request reprint An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Neurooncol 92:149-55. 2009
    ..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies...
  31. doi request reprint Neurological adverse effects caused by cytotoxic and targeted therapies
    David Schiff
    Department of Neurology, University of Virginia in Charlottesville, VA 22908 0432, USA
    Nat Rev Clin Oncol 6:596-603. 2009
    ..These agents include DNA-damaging agents such as oxaliplatin and temozolomide, microtubule poisons like ixabepilone, proteasome inhibitors (bortezomib), and signal transduction inhibitors such as imatinib, sunitinib and bevacizumab...
  32. pmc Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
    Neuro Oncol 10:300-8. 2008
    ..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment...
  33. pmc Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03
    Eudocia Q Lee
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:6032-9. 2012
    ..A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)...
  34. doi request reprint Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Leuk Lymphoma 54:58-61. 2013
    ..Given the overall modest activity, this regimen should be reserved for patients who are not candidates for other, more aggressive salvage treatments...
  35. doi request reprint Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 106:121-5. 2012
    ..03 and 0.02, respectively). Anticoagulant use during BVZ therapy may increase the risk of hemorrhage in glioma patients, although it is generally well tolerated...
  36. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  37. doi request reprint A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:222-7. 2009
    ....
  38. ncbi request reprint Phase I study of GRN1005 in recurrent malignant glioma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:1567-76. 2013
    ..We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma...
  39. pmc Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
    Eudocia Q Lee
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
    Neuro Oncol 14:1511-8. 2012
    ..Minimal activity in recurrent glioblastoma multiforme was seen at the MTD of the 2 combined agents...
  40. pmc Prospective, high-throughput molecular profiling of human gliomas
    Andrew S Chi
    Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Neurooncol 110:89-98. 2012
    ....
  41. pmc Morphological characteristics of brain tumors causing seizures
    Jong Woo Lee
    Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arch Neurol 67:336-42. 2010
    ..To quantify size and localization differences between tumors presenting with seizures vs nonseizure neurological symptoms...
  42. ncbi request reprint Antiangiogenic strategies for treatment of malignant gliomas
    Andrew S Chi
    Stephen E and Catherine Pappas Center for Neuro Oncology, Dept of Neurol, Div of Hematol, and Oncol, Massachusetts General Hosp, Cancer Ctr, Boston, MA 02115 Dana Farber Harvard Cancer Ctr, Brigham and Women s Hosp, Boston, MA 02115 Harvard Med School, Brigham and Women s Hosp, Boston, MA 02115, USA
    Neurotherapeutics 6:513-26. 2009
    ....
  43. doi request reprint Antiangiogenic therapy in malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 20:652-61. 2008
    ..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy...
  44. pmc Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2
    Brian M Alexander
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:972-8. 2013
    ..The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology. ..
  45. pmc Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation
    Marco C Pinho
    Departments of Radiology, Neurology, and Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA Athinoula A Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA The Intervention Centre, Oslo University Hospital, Oslo, Norway Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 19:75-81. 2014
    ..The frequency of PsP was significantly higher in the control group. Conclusion. Administration of a VEGF inhibitor during and after CRT modifies the expression of PsP by imaging. ..
  46. doi request reprint Update on bevacizumab and other angiogenesis inhibitors for brain cancer
    Mikael L Rinne
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA, USA
    Expert Opin Emerg Drugs 18:137-53. 2013
    ..Anti-angiogenic therapy has been a major clinical research focus in neuro-oncology over the past 5 years...
  47. doi request reprint Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas
    Rohit R Das
    Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 107:565-70. 2012
    ..Although clinicians are able to identify patients at high risk for postoperative seizures, treatment with AEDs is ineffective in many patients...
  48. ncbi request reprint Novel anti-angiogenic therapies for malignant gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet Neurol 7:1152-60. 2008
    ..Normalisation of dilated and leaky tumour vasculature might also enable anti-angiogenic therapy to increase the efficacy of radiation therapy and cytotoxic chemotherapy...
  49. pmc Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 27:3518-25. 2009
    ..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...
  50. ncbi request reprint Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 144:895-903. 2009
    ..Bortezomib-associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma. Dose modification using a specific guideline improves peripheral neuropathy management without adversely affecting outcome...
  51. ncbi request reprint Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas
    Deviney Chaponis
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA, USA
    J Neurooncol 104:179-89. 2011
    ..These data support the continued research of high grade glioma treatment combinations of farnesyl transferase inhibitors, temozolomide, and radiation therapy...
  52. pmc Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts P Y W, A D N, J D Department of Neurosurgery, University of California, San Francisco, San Francisco, California S M C, K R L, M D P University of Texas Health Science Center, San Antonio, Texas J G K Division of Neuro Oncology, Department of Neurology, University of California, Los Angeles, Los Angeles, California T F C University of Wisconsin, Madison Wisconsin H I R, M P M Neurooncology Program, Division of Hematology Oncology, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, Pennsylvania F S L Division of Neuro Oncology, MD Anderson Cancer Center, Houston, Texas M R G, M D G, W K A Y, K D A Center for Molecular Oncologic Pathology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts S S, A H L Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts S S, A H L, K L L Investigational Drug Branch
    Neuro Oncol 16:567-78. 2014
    ..Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma patients...
  53. ncbi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
    ..In this report, the second in a two-part series, we review clinical trials of brain metastases in relation to measures of clinical benefit and provide a framework for the design and conduct of future trials. ..
  54. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  55. pmc Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape
    Emmanuelle di Tomaso
    Department of Radiation Oncology, Massachusetts General Hospital and Massachusetts Institute of Technology, Boston, Massachusetts 02114, USA
    Cancer Res 71:19-28. 2011
    ....
  56. ncbi request reprint Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide
    Michelle L Monje
    Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 84:179-83. 2007
    ..Radiation-induced high-grade gliomas are a rare but serious late complication of radiotherapy. We report a patient with radiation-induced cerebellar high-grade glioma who had a durable response to temozolomide...
  57. ncbi request reprint Advances in meningioma therapy
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 9:231-40. 2009
    ..Angiogenesis inhibitors, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments appear promising...
  58. ncbi request reprint Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, 02114 MA, USA
    J Neurooncol 94:97-101. 2009
    ..Presence of psPD, independent of treatment, was associated with prolonged progression-free survival (P = 0.05) but not OS. psPD may be more common in combination therapy but most likely by a small margin...
  59. pmc Colon perforation during antiangiogenic therapy for malignant glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neuro Oncol 11:92-5. 2009
    ..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints...
  60. pmc Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
    Kyrre E Emblem
    1 Department of Radiology and Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA 2 The Intervention Centre, Oslo University Hospital, Oslo, Norway
    Nat Med 19:1178-83. 2013
    ..Thus, VAI has the potential to identify patients who would benefit from therapies. ..
  61. doi request reprint Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
    David A Reardon
    Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue SW G460F, Boston, MA 02215, USA
    Cancer Chemother Pharmacol 69:849-60. 2012
    ..The primary objective of the study was to determine the maximum tolerated dose (MTD) of ridaforolimus...
  62. pmc Longitudinal MRI evidence for decreased survival among periventricular glioblastoma
    Geoffrey S Young
    Department of Radiology, Division of Neuroradiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Neurooncol 104:261-9. 2011
    ..These results suggest that GBMs in close proximity to the ependymal surface of the ventricles convey a worse prognosis-an observation that may be useful for stratifying treatment...
  63. pmc A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430 D, Boston, MA 02115, USA
    Neuro Oncol 13:437-46. 2011
    ..05- and 1.12-fold, respectively, from baseline during AMG 102 treatment. AMG 102 monotherapy at doses up to 20 mg/kg was not associated with significant antitumor activity in heavily pretreated patients with recurrent GBM...
  64. ncbi request reprint Therapy for recurrent malignant glioma in adults
    Maciej M Mrugala
    Harvard Medical School, Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    Expert Rev Anticancer Ther 4:759-82. 2004
    ..Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies...
  65. pmc Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
    Brian J Scott
    Lahey Clinic Medical Center, Department of Neurology, 41 Mall Road, Burlington, MA 01805, USA
    Neuro Oncol 12:603-7. 2010
    ..3-28.9+). Bevacizumab retains modest activity in high-grade glioma patients who progress on R-TKi. However, the APF6 of 12.5% in this cohort of patients indicates that durable tumor control is not achieved for most patients...
  66. ncbi request reprint Antiangiogenic therapies for high-grade glioma
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Nat Rev Neurol 5:610-20. 2009
    ..The international Response Assessment in Neuro-Oncology Working Group has developed consensus treatment response criteria for HGG that account for the complex effects of antiangiogenic drugs...
  67. ncbi request reprint Novel therapies for malignant gliomas
    Robert Cavaliere
    Division of Neuro Oncology, Ohio State University, 463 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Neurol Clin 25:1141-71, x. 2007
    ..Yet much research is still needed at all levels, from the identification of molecular markers to the development and application of novel therapeutics...
  68. pmc Bayesian adaptive randomized trial design for patients with recurrent glioblastoma
    Lorenzo Trippa
    Dana Farber Cancer Institute, Harvard School of Public Health and Dana Farber Brigham and Women s Cancer Center, Boston, MA 02215, USA
    J Clin Oncol 30:3258-63. 2012
    ..To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow for more efficient trials...
  69. pmc Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    Igor Vivanco
    Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:458-71. 2012
    ....
  70. ncbi request reprint Inhibition of angiogenesis and invasion in malignant gliomas
    Andrew Chi
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 7:1537-60. 2007
    ..Combination therapy with antiangiogenic and novel anti-invasion agents is a promising approach that may produce a synergistic antitumor effect and a survival benefit for patients with these devastating tumors...
  71. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  72. ncbi request reprint Non-cytotoxic drugs as potential treatments for gliomas
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Cancer Institute, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 17:663-73. 2004
    ..This review summarizes the most recent developments in non-cytotoxic therapy for malignant gliomas, such as targeted molecular drugs, inhibitors of angiogenesis and intratumoral therapy...
  73. ncbi request reprint Targeted drug therapy for meningiomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Neurosurg Focus 23:E12. 2007
    ..Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed...
  74. doi request reprint Central nervous system complications of cancer therapy
    Mikael L Rinne
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Support Oncol 10:133-41. 2012
    ..This review highlights the CNS complications that result from radiation, chemotherapy, and novel therapeutics...
  75. pmc Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss
    Matija Snuderl
    Pathology Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2698, USA
    Clin Cancer Res 15:6430-7. 2009
    ..The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion...
  76. ncbi request reprint Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    J Neurooncol 88:175-83. 2008
    ..We retrospectively evaluated the clinical, radiographic, histologic, and treatment features from 101 adults with presumed or biopsy proven BSG to determine prognostic factors...
  77. ncbi request reprint Brain metastases
    Andrew D Norden
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Curr Opin Neurol 18:654-61. 2005
    ..The management of patients with multiple metastases, poor prognostic factors, or unresectable lesions is, however, controversial. Recently published data will be reviewed...
  78. ncbi request reprint Glioma therapy in adults
    Andrew D Norden
    Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
    Neurologist 12:279-92. 2006
    ..Despite recent advances, two-year survival for glioblastoma with optimal therapy is less than 30%. Even among patients with low-grade gliomas that confer a relatively good prognosis, treatment is almost never curative...
  79. ncbi request reprint Targeted molecular therapy of malignant gliomas
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Curr Neurol Neurosci Rep 5:186-97. 2005
    ..This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness...
  80. doi request reprint Response assessment in neuro-oncology
    Eudocia C Quant
    Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 13:50-6. 2011
    ..This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma...
  81. ncbi request reprint Cerebrospinal fluid spread of anaplastic glioma
    Ozden Narin
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA, USA
    J Clin Oncol 25:596-7. 2007
  82. ncbi request reprint Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives
    David P Samuel
    Harvard Medical School, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
    Expert Opin Investig Drugs 18:973-83. 2009
    ....
  83. ncbi request reprint Response criteria for glioma
    A Gregory Sorensen
    Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Oncol 5:634-44. 2008
    ....
  84. doi request reprint Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass
    Santosh Kesari
    Department of Neurology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 26:3279-81. 2008
  85. doi request reprint Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  86. doi request reprint Therapeutic strategies for inhibiting invasion in glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston MA 02115, USA
    Expert Rev Neurother 9:519-34. 2009
    ..Recently, there has been important progress in understanding the molecular determinants of glioma invasion and migration. This review will summarize some of the therapeutic strategies for inhibiting invasion in glioblastomas...
  87. ncbi request reprint Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials
    Eudocia C Quant
    Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, SW 430D, Boston, MA 02115, USA
    Neuroimaging Clin N Am 20:425-48. 2010
    ..This article reviews novel therapies for glioblastoma, with an emphasis on targeted agents...
  88. pmc Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
    Gaurav D Shah
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Neuro Oncol 8:38-46. 2006
    ..Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors...
  89. ncbi request reprint American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section
    Patrick Y Wen
    Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 10:1367-9. 2010
    ..Two Phase III studies reported on the relative benefits of radiotherapy and chemotherapy in elderly patients with glioblastomas. Other studies focused on promising new agents such as XL184 and ANG1005...
  90. ncbi request reprint Chemotherapy and targeted molecular therapies for brain metastases
    Jan Drappatz
    Center for Neuro Oncology Dana Farber Brigham and Women s Cancer Center, and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Expert Rev Neurother 6:1465-79. 2006
    ..In this review, the current role of chemotherapy and targeted molecular agents for brain metastases is summarized and future directions are discussed...
  91. ncbi request reprint Recurrent high-grade glioma
    Eudocia C Quant
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430B, 44 Binney Street, Boston, MA, 02115, USA
    Curr Treat Options Neurol 12:321-33. 2010
    ....
  92. ncbi request reprint Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
    Elizabeth A Maher
    Center for Neuro Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 66:11502-13. 2006
    ..We conclude that glioblastoma is composed of at least three distinct molecular subtypes, including novel subgroups of secondary glioblastoma, which may benefit from different therapeutic strategies...
  93. ncbi request reprint Inhibiting kinases in malignant gliomas
    Andrew S Chi
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430D, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Ther Targets 11:473-96. 2007
    ..This article reviews the important protein kinases in malignant gliomas, summarizes the existing clinical development of kinase inhibitors and discusses strategies to improve their effectiveness...
  94. doi request reprint Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
    Camilo E Fadul
    Neuro Oncology Program, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
    J Neurooncol 89:339-57. 2008
  95. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  96. ncbi request reprint Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
    Howard A Fine
    Neuro Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1911, Building 10, Room 12S245, Bethesda, MD 20892 1911, USA
    J Clin Oncol 21:2299-304. 2003
    ....
  97. ncbi request reprint Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  98. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  99. pmc A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
    ..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population...
  100. ncbi request reprint The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas
    Teri T B Ngo
    Surgical and Molecular Neuro oncology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 99:639-52. 2007
    ....

Research Grants2

  1. THERAPEUTICS STUDIES OF PRIMARY CNS MALIGNANCIES
    Patrick Wen; Fiscal Year: 2007
    ..abstract_text> ..
  2. THERAPEUTICS STUDIES OF PRIMARY CNS MALIGNANCIES
    Patrick Wen; Fiscal Year: 2008
    ..abstract_text> ..